Pathogen Detection and Community Acquired Pneumonia



Status:Active, not recruiting
Conditions:Pneumonia
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:Any
Updated:6/9/2018
Start Date:January 2017
End Date:December 2018

Use our guide to learn which trials are right for you!

Projected Influence of Enhanced Pathogen Detection on the Clinical Management of Community-Acquired Pneumonia

Study to compare the number of community-acquired pneumonia (CAP) pathogens detected using
current diagnostic tests to the number detected using the BioFire Diagnostics investigational
polymerase chain reaction (PCR) platform.

Patients diagnosed in the emergency department with CAP that requires hospitalization provide
a sputum sample for culture and sensitivity testing, urine for detection of S. pneumonia and
L. pneumophila, an anterior nasal swab for S. aureus PCR, a nasopharyngeal swab for S.
pneumonia PCR and the FilmArray LRTI v.2.0 IUO Panel, and blood for procalcitonin testing
and, in cases in which the patient is suffering rigors and hypotension, cultures. As part of
this study, sputum or sputum equivalent will be acquired for testing using the FilmArray LRTI
v.2.0 IUO Panel.

Inclusion Criteria:

- Emergency Department physician diagnosis of CAP requiring hospitalization

Exclusion Criteria:

- Inability to obtain sputum or sputum equivalent
We found this trial at
1
site
Portland, Oregon 97213
?
mi
from
Portland, OR
Click here to add this to my saved trials